Gemma Manich

Dr. Gemma Manich

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2010 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
JMJaume del Valle Macià
Jaume del Valle Macià
JDJoaquim Duran-Vilaregut
Joaquim Duran-Vilaregut
GMGemma Manich
Gemma Manich
GCGemma Casadesús
Gemma Casadesús
MSMark A. Smith
Mark A. Smith
JVJordi Vilaplana
Jordi Vilaplana
Late-onset Alzheimer's disease (AD) is the most common form of AD appearing after 65 years of age. To date, however, there are no non-genetically manipulated rodent models that develop a similar sporadic onset of AD with age-related amyloid-β (Aβ) de

1 May 2019 in Neuroscience
Verified
Journal Article
Closed access
GMGemma Manich
Gemma Manich
MRMireia Recasens
Mireia Recasens
TVTony Valente
Tony Valente
BABeatriz Almolda
Beatriz Almolda
BGBerta González
Berta González
BCBernardo Castellano
Bernardo Castellano

8 July 2011 in Journal of Alzheimer’s Disease
Verified
Journal Article
Open access
PDF file
GMGemma Manich
Gemma Manich
CMClara Mercader
Clara Mercader
JMJaume del Valle Macià
Jaume del Valle Macià
JDJoaquim Duran-Vilaregut
Joaquim Duran-Vilaregut
Antoni CaminsAntoni Camins
Antoni Camins
CPCarme Pelegrí
Carme Pelegrí
The senescence accelerated mouse-prone 8 (SAMP8) strain of mice is an experimental model of accelerated senescence that has also been proposed as a model of Alzheimer's disease as it shares several features with this dementia. We have recently report

13 July 2011 in Neuropathology and Applied Neurobiology
Verified
Journal Article
Closed access
PDF file
JDJ. Duran‐Vilaregut
J. Duran‐Vilaregut
JMJaume del Valle Macià
Jaume del Valle Macià
GMGemma Manich
Gemma Manich
Antoni CaminsAntoni Camins
Antoni Camins
Merce PallasMerce Pallas
Merce Pallas
CPCarme Pelegrí
Carme Pelegrí

16 March 2011 in Neurodegenerative Diseases
Verified
Journal Article
Closed access
JMJaume del Valle Macià
Jaume del Valle Macià
JDJoaquim Duran-Vilaregut
Joaquim Duran-Vilaregut
GMGemma Manich
Gemma Manich
Merce PallasMerce Pallas
Merce Pallas
Antoni CaminsAntoni Camins
Antoni Camins
CPCarme Pelegrí
Carme Pelegrí
Cerebrovascular dysfunction and β-amyloid peptide deposition on the walls of cerebral blood vessels might be an early event in the development of Alzheimer’s disease. Here we studied the time course of amyloid deposition in blood vessels and blood-brain barrier (BBB) disruption in the CA1 subzone of the hippocampus of SAMP8 mice and the association between these two variables. We also studied the association between the amyloid deposition in blood vessels and the recently described amyloid clusters in the parenchyma, as well as the association of these clusters with vessels in which the BBB is disrupted. SAMP8 mice showed greater amyloid deposition in blood vessels than age-matched ICR-CD1 control mice. Moreover, at 12 months of age the number of vessels with a disrupted BBB had increased in both strains, especially SAMP8 animals. At this age, all the vessels with amyloid deposition showed BBB disruption, but several capillaries with an altered BBB showed no amyloid on their walls. Moreover, amyloid clusters showed no spatial association with vessels with amyloid deposition, nor with vessels in which the BBB had been disrupted. Finally, we can conclude that vascular amyloid deposition seems to induce BBB alterations, but BBB disruption may also be due to other factors.

1 July 2013 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
GMGemma Manich
Gemma Manich
ICItsaso Cabezón
Itsaso Cabezón
JMJaume del Valle Macià
Jaume del Valle Macià
JDJoaquim Duran-Vilaregut
Joaquim Duran-Vilaregut
Antoni CaminsAntoni Camins
Antoni Camins
JVJordi Vilaplana
Jordi Vilaplana